Page last updated: 2024-09-03

imatinib mesylate and Impotence, Arteriogenic

imatinib mesylate has been researched along with Impotence, Arteriogenic in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Gur, S; Hellstrom, WJ; Kadowitz, PJ	1

Other Studies

1 other study(ies) available for imatinib mesylate and Impotence, Arteriogenic

Article	Year
A protein tyrosine kinase inhibitor, imatinib mesylate (Gleevec), improves erectile and vascular function secondary to a reduction of hyperglycemia in diabetic rats. The journal of sexual medicine, 2010, Volume: 7, Issue:10 Topics: Animals; Benzamides; Blood Glucose; Diabetes Mellitus, Experimental; Dose-Response Relationship, Drug; Hyperglycemia; Imatinib Mesylate; Impotence, Vasculogenic; Male; Penile Erection; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Rats; Rats, Sprague-Dawley	2010

Article

Year

A protein tyrosine kinase inhibitor, imatinib mesylate (Gleevec), improves erectile and vascular function secondary to a reduction of hyperglycemia in diabetic rats.

The journal of sexual medicine, 2010, Volume: 7, Issue:10

Topics: Animals; Benzamides; Blood Glucose; Diabetes Mellitus, Experimental; Dose-Response Relationship, Drug; Hyperglycemia; Imatinib Mesylate; Impotence, Vasculogenic; Male; Penile Erection; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Rats; Rats, Sprague-Dawley

2010